APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas-Reference-Cited by-同舟云学术

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas

Published:2022-12 Issue:12 Volume:33 Page:1284-1295
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Selenica P.,Marra A.,Choudhury N.J.,Gazzo A.,Falcon C.J.,Patel J.,Pei X.,Zhu Y.,Ng C.K.Y.,Curry M.,Heller G.,Zhang Y.-K.,Berger M.F.,Ladanyi M.,Rudin C.M.,Chandarlapaty S.,Lovly C.M.,Reis-Filho J.S.,Yu H.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference46 articles.

1. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer;Schoenfeld;Clin Cancer Res,2020

2. Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer;Roper;Cell Rep Med,2020

3. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution;de Bruin;Science,2014

4. APOBEC Enzymes: mutagenic fuel for cancer evolution and heterogeneity;Swanton;Cancer Discov,2015

5. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing;Zhang;Science,2014

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations;The Oncologist;2024-06-22

2. Cancer mutational signatures identification in clinical assays using neural embedding-based representations;Cell Reports Medicine;2024-06

3. UNG-RPA interaction governs the choice between high-fidelity and mutagenic uracil repair;2024-05-03

4. APOBEC3 mutagenesis drives therapy resistance in breast cancer;2024-05-01

5. Targeting APOBECs in cancer: It’s about timing;Cancer Cell;2024-04